235 related articles for article (PubMed ID: 8152797)
1. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.
Huang RP; Darland T; Okamura D; Mercola D; Adamson ED
Oncogene; 1994 May; 9(5):1367-77. PubMed ID: 8152797
[TBL] [Abstract][Full Text] [Related]
2. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain.
Huang RP; Liu C; Fan Y; Mercola D; Adamson ED
Cancer Res; 1995 Nov; 55(21):5054-62. PubMed ID: 7585551
[TBL] [Abstract][Full Text] [Related]
3. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
4. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity.
Liu C; Calogero A; Ragona G; Adamson E; Mercola D
Crit Rev Oncog; 1996; 7(1-2):101-25. PubMed ID: 9109500
[TBL] [Abstract][Full Text] [Related]
5. Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2.
Sonobe MH; Bravo R; Armelin MS
Oncogene; 1991 Sep; 6(9):1531-7. PubMed ID: 1923519
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal modulation between Sp1 and Egr-1.
Huang RP; Fan Y; Ni Z; Mercola D; Adamson ED
J Cell Biochem; 1997 Sep; 66(4):489-99. PubMed ID: 9282327
[TBL] [Abstract][Full Text] [Related]
7. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis.
de Belle I; Huang RP; Fan Y; Liu C; Mercola D; Adamson ED
Oncogene; 1999 Jun; 18(24):3633-42. PubMed ID: 10380885
[TBL] [Abstract][Full Text] [Related]
8. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
9. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
10. Rapid, complete and reversible transformation by v-sis precedes irreversible transformation.
Mercola D; Carpenter PM; Grover-Bardwick A; Mercola M
Oncogene; 1992 Sep; 7(9):1793-803. PubMed ID: 1501889
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Egr-1-dependent gene expression by the C-terminal activation domain.
Gosslar U; Schmid RM; Holzmann B
Biochem Biophys Res Commun; 1999 Feb; 255(2):208-15. PubMed ID: 10049687
[TBL] [Abstract][Full Text] [Related]
13. Activated mutant of G alpha 13 induces Egr-1, c-fos, and transformation in NIH 3T3 cells.
Vara Prasad MV; Shore SK; Dhanasekaran N
Oncogene; 1994 Aug; 9(8):2425-9. PubMed ID: 8036026
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
Worden B; Yang XP; Lee TL; Bagain L; Yeh NT; Cohen JG; Van Waes C; Chen Z
Cancer Res; 2005 Aug; 65(16):7071-80. PubMed ID: 16103054
[TBL] [Abstract][Full Text] [Related]
15. A biological role for Egr-1 in cell survival following ultra-violet irradiation.
Huang RP; Adamson ED
Oncogene; 1995 Feb; 10(3):467-75. PubMed ID: 7845671
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells.
Maroney AC; Qureshi SA; Foster DA; Brugge JS
Oncogene; 1992 Jun; 7(6):1207-14. PubMed ID: 1375718
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Egr-1 (Zfp-6) and c-fos expression in differentiating embryonal carcinoma cells.
Darland T; Samuels M; Edwards SA; Sukhatme VP; Adamson ED
Oncogene; 1991 Aug; 6(8):1367-76. PubMed ID: 1909429
[TBL] [Abstract][Full Text] [Related]
19. [The antibodies obtained by immunization with a peptide identical to a section of the zinc-binding domain of the early growth response 1 factor (EGR-1) interact with a 102-kDa protein from mouse fibroblasts].
Popov BV; Kaczmarek L
Tsitologiia; 1994; 36(5):453-8. PubMed ID: 7809981
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells.
Potapova O; Fakhrai H; Baird S; Mercola D
Cancer Res; 1996 Jan; 56(2):280-6. PubMed ID: 8542581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
